CeleCor Therapeutics develops first-point contact treatments for segment elevated myocardial infarction.
CeleCor Therapeutics has raised $11.9M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in July 2026.
CeleCor Therapeutics is headquartered in Del Mar, United States.
CeleCor Therapeutics develops first-point contact treatments for segment elevated myocardial infarction.
CeleCor Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CeleCor Therapeutics — Funding & Investors." VCBacked, July 9, 2026, https://www.vcbacked.co/company/celecor-therapeutics. Accessed August 13, 2026.
VCBacked. (2026). CeleCor Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/celecor-therapeutics
{{cite web |title=CeleCor Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/celecor-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated